Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025

OMEROS CORP

2025-Q1 EPS reported -$0.58

Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.
Cash and investments $90.1M at Dec 31, 2024, down $81.7M from year-end 2023; $42.7M cost outlays.
OMIDRIA royalties Q4 $10.1M on Rayner sales $33.6M, up from $9.3M on $31.0M in Q3.
BLA for narsoplimab in TA-TMA resubmitted to FDA Mar 2025; PDUFA target September 2025.
Phase 3 for zaltenibart in PNH initiated; NIDA awarded $4.02M for OMS527 CUD study; data readout by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.